A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders.

Trial Profile

A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs Gandotinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2018.
    • 09 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 05 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top